logo
Amrize Debuts as Independent, Publicly Traded Company

Amrize Debuts as Independent, Publicly Traded Company

Yahoo13 hours ago

100% spin-off from Holcim complete
Amrize begins trading on NYSE and SIX under ticker symbol "AMRZ"
Amrize to be the partner of choice for North America's professional builders
NEW YORK & ZURICH, June 23, 2025--(BUSINESS WIRE)--Amrize announces its debut today as an independent, publicly traded company with the completion of its 100% spin-off from Holcim. Amrize shares will begin trading today on the New York Stock Exchange (NYSE) and the SIX Swiss Exchange under the ticker symbol "AMRZ."
Amrize is building North America, as the partner of choice for professional builders with advanced branded solutions from foundation to rooftop. With over 1,000 sites and a highly efficient distribution network, Amrize delivers for its customers in every U.S. state and Canadian province. Its 19,000 teammates uniquely serve every construction market from infrastructure, commercial and residential to new build, repair and refurbishment.
Jan Jenisch, Amrize Chairman and CEO: "This is an exciting day for all our teammates across North America as we begin our journey together as Amrize. As an independent, publicly traded company, Amrize will capitalize on North America's attractive construction market driven by long term mega-trends from infrastructure modernization and onshoring of manufacturing to data center expansion and the opportunity to bridge the housing gap. With our track record of profitable growth, market-leading operations and broad range of advanced building solutions, we are ideally positioned to be the partner of choice for the professional builders of North America and to unlock value for all stakeholders.
"It has been a privilege to be part of Holcim since 2017 and I thank the entire Holcim team for their outstanding performance and contributions over the years, including the exceptional execution of our spin-off creating two distinct, independent champions. I wish the Holcim team every success as they begin their next chapter."
The spin-off is completed via the distribution of a dividend-in-kind of one Amrize share for every Holcim share owned as of the close of business on June 20, 2025.
In 2024, Amrize generated $11.7 billion in revenue, a 13% CAGR from 2021; and achieved $3.2 billion in Adjusted EBITDA1, a 16% CAGR since 2021, with an overall 27% Adjusted EBITDA Margin2. The company generated $1.7 billion in Free Cash Flow3 in 2024, a 15% CAGR since 2021, and has consistently delivered Adjusted EBITDA Cash Conversion Ratio4 of more than 50% each year. The company has completed 36 acquisitions since 2018.
Amrize presented its business strategy and mid-term financial targets at its investor day in New York on March 25. Now an independent, publicly traded company, Amrize will continue to deliver superior performance and value creation with above market growth, margin expansion and leading cash generation. It will pursue a growth-focused strategy with capital allocation prioritizing investments in the business, value accretive M&A and superior shareholder returns.
Company leaders will mark the milestone by ringing the NYSE opening bell today at 9:30 am ET. Amrize leaders will then visit sites across the U.S. and Canada to celebrate and thank teammates.
About Amrize
Amrize (NYSE: AMRZ) is building North America, as the partner of choice for professional builders with advanced branded solutions from foundation to rooftop. With over 1,000 sites and a highly efficient distribution network, we deliver for our customers in every U.S. state and Canadian province. Our 19,000 teammates uniquely serve every construction market from infrastructure, commercial and residential to new build, repair and refurbishment. Amrize achieved $11.7 billion in revenue in 2024 and is listed on the New York Stock Exchange and the SIX Swiss Exchange. We are ready to build your ambition.
Learn more at amrize.com
Important disclaimer – forward-looking statements:
This media release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements do not constitute forecasts and include all statements that are not historical statements of fact and those regarding our intent, belief, targets or expectations, including, but not limited to: future commercial or financial performance or the anticipated benefits or effects of the spin-off; Amrize's expected areas of focus and strategy to drive growth and profitability and create long-term shareholder value; the impact of planned acquisitions and divestments and any other statements regarding Amrize's future operations, anticipated business levels, planned activities, anticipated growth, market opportunities, strategies and other expectations. Although Amrize believes that the expectations reflected in such forward-looking statements are based on reasonable assumptions as at the time of publishing this media release, investors are cautioned that these statements are not guarantees of future performance. No assurance can be given that any plan, initiative, projection, goal, commitment, expectation or prospect set forth in this media release can or will be achieved, or that Amrize will be able to realize any strategic benefits or opportunities as a result of these actions. Neither can there be any guarantee that shareholders will achieve any particular level of returns, or that Amrize will be commercially successful in the future or achieve any particular financial result. We caution investors not to place undue reliance on any such forward-looking statements.
Words such as "anticipate(s)," "expect(s)," "intend(s)," "believe(s)," "plan(s)," "may," "will," "would," "could," "should," "seek(s)," and similar expressions, or the negative of these terms, are intended to identify such forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks and uncertainties that could lead to actual results differing materially from those forecasted or expected. Although we believe that the assumptions underlying the forward-looking statements are reasonable, we can give no assurance that our expectations will be attained, and Amrize assumes no (and disclaims any) obligation to revise or update such forward-looking statements to reflect future events or circumstances. We make no representations or warranties as to the accuracy of any statements or information contained in this media release.
Important factors that could cause actual results to differ from those in our forward-looking statements include, without limitation: 1) the effect of political, economic and market conditions and geopolitical events, 2) the logistical and other challenges inherent in our operations, 3) the actions and initiatives of current and potential competitors, 4) the level and volatility of, interest rates and other market indices, 5) the outcome of pending litigation, 6) the impact of current, pending and future legislation and regulation, 7) factors related to the failure of Amrize to achieve some or all of the expected strategic benefits or opportunities expected from the separation, 8) that Amrize may incur material costs and expenses as a result of the separation, 9) that Amrize has no history operating as an independent, publicly traded company, 10) that Amrize's historical and pro forma financial information is not necessarily representative of the results that it would have achieved as a separate, publicly traded company and therefore may not be a reliable indicator of its future results, 11) Amrize's obligation to indemnify Holcim pursuant to the agreements entered into connection with the separation and the risk Holcim may not fulfill any obligations to indemnify Amrize under such agreements, 12) that under applicable tax law, Amrize may be liable for certain tax liabilities of Holcim following the separation if Holcim were to fail to pay such taxes, 13) the fact that Amrize may receive worse commercial terms from third-parties for services it presently receives from Holcim, 14) that after the separation, certain of Amrize's executive officers and directors may have actual or potential conflicts of interest because of their previous positions at Holcim, 15) potential difficulties in maintaining relationships with key personnel and 16) that Amrize will not be able to rely on the earnings, assets or cash flow of Holcim and Holcim will not provide funds to finance Amrize's working capital or other cash requirements.
Readers should carefully review the final information statement relating to the spin-off, including but not limited to the matters described under "Risk Factors", "Management's Discussion and Analysis of Financial Condition and Results of Operations" and in other sections. The final information statement identifies and addresses other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. A copy of the final information statement has been filed with the SEC as Exhibit 99.1 to the Current Report on Form 8-K dated June 2, 2025 and is available at www.sec.gov.
This media release does not constitute an offer to sell, or a solicitation of an offer to buy or subscribe for, any securities nor shall it or any part of it nor the fact of its distribution form the basis of, or be relied on, in connection with any contract therefore. This media release does not constitute a prospectus as defined in the Swiss Financial Services Act of 15 June 2018 or a prospectus under the securities laws and regulations of the United States or any other laws. This media release does not constitute a recommendation with respect to the shares of Amrize.
Non-GAAP Financial Measures
This media release contains certain financial measures of historical performance and financial positions that are not prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP"). We refer to these measures as "non-GAAP" financial measures. Management believes that these non-GAAP financial measures are useful information to help describe the performance of Amrize.
These non-GAAP financial measures should not be considered as alternatives to financial measures prepared in accordance with U.S. GAAP. The reasons Amrize uses these non-GAAP financial measures are included in Amrize's final information statement filed with the SEC and the reconciliations to their most directly comparable GAAP financial measures are included below.
Definitions of Non-GAAP Financial Measures:
EBITDA is defined as Net income (loss), excluding Depreciation, depletion, accretion and amortization, Interest expense, net and Income tax benefit (expense).
1 Adjusted EBITDA is defined as Segment Adjusted EBITDA including unallocated corporate costs. Segment Adjusted EBITDA is defined as Net income (loss), excluding unallocated corporate costs, Depreciation, depletion, accretion and amortization, Loss on impairments, Other non-operating income (expense), net, Interest expense, net, Income tax benefit (expense), Income from equity method investments, and certain other items, such as costs related to acquisitions, certain litigation costs, restructuring costs, charges associated with non-core sites and certain warranty charges related to a pre-acquisition manufacturing issue and transaction costs related to the spin-off.
2 Adjusted EBITDA Margin is defined as Adjusted EBITDA divided by revenues.
3 Free Cash Flow is defined net cash provided by (used in) operating activities plus proceeds from property and casualty insurance, proceeds from land expropriation and proceeds from disposals of long-lived assets less purchases of property, plant and equipment.
4 Adjusted EBITDA Cash Conversion Ratio is defined as Free Cash Flow divided by Adjusted EBITDA.
Reconciliation of Non-GAAP Financial Measures
The table below reconciles our net income and net income margin, the most directly comparable financial measures calculated in accordance with U.S. GAAP, to Adjusted EBITDA and Adjusted EBITDA Margin, respectively.
For the years ended December 31,
(In millions, except for percentage data)
2024
2023
2022
Net income
$1,273
$955
$1,107
Depreciation, depletion, accretion and amortization
889
851
788
Interest expense, net
512
549
248
Income tax expense
368
361
366
EBITDA
3,042
2,716
2,509
Loss on impairments
2
15
57
Other non-operating (income) expense, net(1)
55
36
(9)
Income from equity method investments
(13)
(13)
(13)
Other(2)
95
90
55
Adjusted EBITDA
3,181
2,844
2,599
Unallocated corporate costs
141
155
112
Total Segment Adjusted EBITDA
$3,322
$2,999
$2,711
Building Materials
2,552
2,314
2,049
Building Envelope
770
685
662
Net income margin
11%
8%
10%
Adjusted EBITDA Margin
27%
24%
24%
(1)
Other non-operating (income) expense, net primarily consists of costs related to pension and other postretirement benefit plans and gains on proceeds from property and casualty insurance.
(2)
Other primarily consists of costs related to acquisitions, certain litigation costs, restructuring costs, charges associated with non-core sites, certain warranty charges related to a pre-acquisition manufacturing issue and transaction costs related to the spin-off.
The table below reconciles our net cash provided by operating activities, the most directly comparable financial measure calculated in accordance with U.S. GAAP, to Free Cash Flow and Adjusted EBITDA Cash Conversion Ratio.
For the years ended December 31,
(In millions, except for percentage data)
2024
2023
2022
Net cash provided by operating activities
$2,282
$2,036
$1,988
Capital expenditures, net(1)
(549)
(581)
(436)
Free cash flow
$1,733
$1,455
$1,552
Net income
1,273
955
1,107
Adjusted EBITDA
3,181
2,844
2,599
Adjusted EBITDA cash conversion ratio
0.54
0.51
0.60
(1) Capital expenditures, net includes purchases of property, plant and equipment, proceeds from property and casualty insurance income, proceeds from land expropriation and proceeds from disposals of long-lived assets.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250622233353/en/
Contacts
Media Relations: media@amrize.com
Investor Relations: investors@amrize.com

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

UBS boosts Aritzia price target, pointing to 'significant' opportunities for U.S. expansion
UBS boosts Aritzia price target, pointing to 'significant' opportunities for U.S. expansion

Yahoo

time12 minutes ago

  • Yahoo

UBS boosts Aritzia price target, pointing to 'significant' opportunities for U.S. expansion

Analysts at UBS Group on Monday hiked their price target for Vancouver-based Aritzia ( from $66 to $95, pointing to significant growth opportunities in the U.S. in the years ahead. Noting a U.S. footprint significantly smaller than similar retailers, a considered expansion strategy and manageable tariff risks, analyst Mauricio Serna reiterated his "Buy" rating for the stock in a note to investors. 'Our view is the U.S. remains a long-term sales growth and margin driver for ATZ,' Serna wrote. 'We believe ATZ still has significant white space opportunities in the U.S., given it only operates 64 stores, with penetration levels well below its closest peers.' Aritzia shares were trading at $67.25 on the Toronto Stock Exchange as at 12:30 p.m. ET Monday. The stock fell below $40 in early April as tariff threats gripped the markets. In May, Aritzia said it had taken steps to minimize tariff impact in the U.S. The company says U.S. operations helped drive a strong first quarter and notes plans to expand into five more U.S. cities. Serna writes that 'ATZ remains under-penetrated vs its closest peers across every region' and highlights Aritzia's past mention of '150 potential real estate opportunities in the U.S.' The company's average pace of 10 new stores per year suggests eight years of expansion runway, Serna says. 'Importantly, we see upside to this figure as we think new locations can become available over time as other players exit the market,' he wrote. Some similar retailers have also tried U.S. expansion and struggled as a consequence, Serna notes. But UBS points to Aritzia taking 'a more prudent approach by being more selective on the location of its boutiques and ensuring the store design and visuals engage its targeted customers.' Aritzia's U.S. growth is central to UBS' forecast for earnings per share to grow at a 20 per cent compound annual growth rate (CAGR) over the next five years, with U.S. sales growing at 15 per cent CAGR over that period. Crucially, UBS estimates that U.S. margins are around 800 basis points higher than those in Canada because Aritzia prices its products at the same number in U.S. and Canadian stores. 'For instance, a customer can purchase a Babaton coat for C$200 in Toronto and will likely find the same product in New York City selling at US$200,' the UBS note said. 'This strategy implies a structural uplift to merchandise margins to Aritzia's U.S. business given a higher selling price but a similar cost base.' Aritzia's e-commerce sales 'materially slowed' in the 2024 fiscal year, Serna writes, but the company has since invested in enhancing its website and more digital marketing. 'We believe ATZ is still in the early innings of unlocking more growth on its digital channel. We see more runway ahead as the company launches a U.S. app in fiscal 2H26.' Though tariff risks exist, Serna estimates the worst-case scenario would result in only a 400 basis point headwind to margins — similar to Aritzia's initial guidance for 2026. John MacFarlane is a senior reporter at Yahoo Finance Canada. Follow him on X @jmacf. Download the Yahoo Finance app, available for Apple and Android. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Buy now, pay later loans will soon impact credit scores
Buy now, pay later loans will soon impact credit scores

Yahoo

time12 minutes ago

  • Yahoo

Buy now, pay later loans will soon impact credit scores

Buy now, pay later (BNPL) could come with new credit consequences as FICO (FICO) is set to roll out a new credit score model that includes BNPL data. Freedom Capital Markets chief global strategist Jay Woods sits down with Market Catalysts host Brad Smith to explain how new FICO changes could legitimize BNPL while exposing risks for borrowers and lenders. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

U.S. Healthcare Payer Analytics Market Forecast Report 2025-2030, with Profiles of CloudMedx, DataSmart Solutions, Amitech Solutions, IMAT Solutions, Indegene, MedeAnalytics, Verisk Analytics, & more
U.S. Healthcare Payer Analytics Market Forecast Report 2025-2030, with Profiles of CloudMedx, DataSmart Solutions, Amitech Solutions, IMAT Solutions, Indegene, MedeAnalytics, Verisk Analytics, & more

Yahoo

time18 minutes ago

  • Yahoo

U.S. Healthcare Payer Analytics Market Forecast Report 2025-2030, with Profiles of CloudMedx, DataSmart Solutions, Amitech Solutions, IMAT Solutions, Indegene, MedeAnalytics, Verisk Analytics, & more

The U.S. Healthcare Payer Analytics Market is projected to grow to USD 19.38 billion by 2030, with a CAGR of 21.50%, driven by digital advancements, record digitization, and fraud prevention. Descriptive analytics leads the market, while hardware and financial applications show rapid growth. Increasing government investment and technological advancements aid decision-making, and the trend towards telehealth and cloud-based solutions fuels market expansion. Key insights include comprehensive market analysis and competitive strategy evaluation. U.S. Healthcare Payer Analytics Market Dublin, June 23, 2025 (GLOBE NEWSWIRE) -- The "U.S. Healthcare Payer Analytics Market Size, Share & Trends Analysis Report by Analytics Type (Descriptive Analytics), Component (Software), Delivery Model, Application with Growth Forecasts, 2025-2030" report has been added to U.S. Healthcare Payer Analytics Market was valued at USD 5.90 billion in 2024, and is projected to reach USD 19.38 billion by 2030, rising at a CAGR of 21.50%. The digital advancements in the healthcare field, and the digitization of records, are one of the key factors driving the growth of this market. Adoption of such technologies is on an upward trend thus propelling the market. Digital data is being used to derive meaningful results, cost reduction, and minimize fraudulent insurance claims. The U.S. government has been increasingly spending on healthcare and focusing on improving digital infrastructure, which is boosting technological advancements in the field. Due to technological advancements, decision-making for payers and healthcare providers has become easier with the help of analytical tools. The overall increase in healthcare expenditure has amounted to more than USD 4 trillion in the year 2020. It is not only helping the healthcare industry develop faster but has also made healthcare more affordable and healthcare analytical tools are helping administrators and policymakers in determining what is the best course of action, how successful is it going to be, and how much cost can be saved by cutting unnecessary expenditures. For insurance companies, analytical tools have helped in recognizing patterns of insurance fraud and in turn saving billions of dollars per year. Doctors' analytical tools have helped to determine the best treatment plans for a particular patient by studying and analyzing their the analytics type, the descriptive analysis held the largest market share of 358% in 2022. Descriptive analytics has been widely used during COVID by various research organizations as well as laboratories, to determine how contagious the virus is by studying the past and present tests being conducted for coronavirus. Descriptive analytics analyzes data to derive meaningful results and can significantly impact future decisions. The fastest-growing was the predictive analytics segment, this helps in charting the best treatment plan for a personalized treatment plan, it can help the doctor to find out what works best for a patient and can give better treatment the components, the service segment dominated the market in 2022. Since the majority of establishments do not have an analytics department, it is generally outsourced to industry experts which saves the cost of training and teaching the staff about tools and methods. The fastest-growing component was the hardware, with rapid investment in healthcare IT, the need for better computers and hardware components has been responsible for the growth of the the largest market share is held by the on-premises delivery model. Healthcare organizations have been opting for the installment of analytical tools and software. The on-premises installation results in less theft of data and provide easier access and maintenance of data and patient records. However, cloud-based storage has been gaining popularity due to ease of storage, and minimum requirement of setup, which has been a key driving factor for the growth of the the applications segment, the largest market share is currently held by financial applications. Private and government facilities have been increasingly adopting analytics for financial applications. Healthcare analytics is being used for claim settlement, risk analysis, and identifying frauds in insurance claims. The fastest-growing application is also financial applications, for use in identifying frauds related to insurance which cost the payers billions of dollars per year. These factors have contributed significantly to the growth of the healthcare payer analytics COVID-19 pandemic created a huge opportunity for the healthcare analytics market. The amount of patient data generated during the pandemic has greatly helped in studying how the disease spreads, how contagious it is, and what implications it can have on people. Economies around the world have suffered gravely due to supply chain disruptions saw a decline in the market, but the usage and rate of adoption of analytics have increased overall. Telehealth, a means to communicate with patients and doctors saw 38 times increase in adoption from pre-COVID times, as per McKinsey.U.S. Healthcare Payer Analytics Market Report Highlights The descriptive analytics segment had the largest market share in 2024. This analytics type is widely used in process optimization and administrative activities. The on-premises segment dominated the market with a share of 47.0% in 2024. The healthcare industry is evolving in terms of technology. Based on application, the financial application segment dominated the market with the largest revenue share in 2024. Based on the components, the services segment had the largest market share of 42.4% in 2024. This report addresses: Market intelligence to enable effective decision-making Market estimates and forecasts from 2018 to 2030 Growth opportunities and trend analyses Segment and regional revenue forecasts for market assessment Competition strategy and market share analysis Product innovation listings for you to stay ahead of the curve Companies Featured The major companies featured in this U.S. Healthcare Payer Analytics market report include: CloudMedx DataSmart Solutions Amitech Solutions Caserta Concepts Greenway Health, LLC IMAT Solutions Health Catalyst Indegene IBM Optum Oracle Citius Tech MedeAnalytics Verisk Analytics, Inc. McKesson Medical-Surgical Inc. Veradigm IQVIA Key Attributes: Report Attribute Details No. of Pages 150 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $5.9 Billion Forecasted Market Value (USD) by 2030 $19.38 Billion Compound Annual Growth Rate 21.5% Regions Covered United States Key Topics Covered: Chapter 1. Methodology and ScopeChapter 2. Executive Summary2.1. Market Snapshot2.2. Segment Snapshot2.3. Competitive Landscape SnapshotChapter 3. Market Variables, Trends, & Scope3.1. Market Lineage Outlook3.2. Market Dynamics3.2.1. Market Driver Analysis3.2.1.1. Growing usage of AI/ML-Driven in payer analytics solutions3.2.1.2. Declining payer profit margins of insurance companies3.2.1.3. Increasing need for risk management and predictive insights3.2.2. Market Restraint Analysis3.2.2.1. Data privacy and Security Concerns3.2.2.2. Shortage of qualified professionals3.2.2.3. Complex regulatory environment3.2.3. Market Opportunity Analysis3.2.3.1. Expansion into predictive and prescriptive analytics3.2.4. Market Threat Analysis3.3. Business Environment AnalysisChapter 4. U.S. Healthcare Payer Analytics Market: Analytics Type Estimates & Trend Analysis4.1. Segment Dashboard4.2. Descriptive Analytics4.3. Predictive Analytics4.4. Prescriptive Analytics4.5. Diagnostic Analytics4.6. Discovery AnalyticsChapter 5. U.S. Healthcare Payer Analytics Market: Component Estimates & Trend Analysis5.1. Component Segment Dashboard5.2. Component Market Share Movement Analysis, 2024 & 20305.3. Market Size & Forecasts and Trend Analysis, by Component, 2018 to 2030 (USD Million)5.4. Software5.5. Hardware5.6. ServicesChapter 6. U.S. Healthcare Payer Analytics Market: Delivery Model Estimates & Trend Analysis6.1. Delivery Model Segment Dashboard6.2. Delivery Model Market Share Movement Analysis, 2024 & 20306.3. Market Size & Forecasts and Trend Analysis, by Delivery Model, 2018 to 2030 (USD Million)6.4. On-premises6.5. Web & cloud-based market, 2018-2030 (USD Million)6.6. Web & cloud-based6.7. Cloud-BasedChapter 7. U.S. Healthcare Payer Analytics Market: Application Estimates & Trend Analysis7.1. Application Segment Dashboard7.2. Application Market Share Movement Analysis, 2024 & 20307.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)7.4. Clinical7.5. Financial7.6. Operational and AdministrativeChapter 8. Competitive Landscape8.1. Participant Overview8.2. Company Market Position Analysis8.3. Company Categorization8.4. Strategy Mapping8.5. Company Profiles For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment U.S. Healthcare Payer Analytics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store